Published by Ministry of Health, Labour and Welfare

62

Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this

English translation, the former shall prevail.

Revision of Precautions Purified tuberculin

July 17, 2019

Therapeutic category

Biological preparations-miscellaneous

Non-proprietary name

Purified tuberculin

Safety measure Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u> Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
Contraindications	Contraindications
(N/A)	Persons who have had a severe reaction such as blistering or
	necrosis to a previous tuberculin test
	In addition to those persons mentioned above, persons in a condition
	where tuberculin testing is considered inappropriate
Relative Contraindications	Relative Contraindications
Persons who have had a severe reaction such as blistering or	(deleted)
necrosis to a previous tuberculin test	
In addition to those persons mentioned above, persons in a condition	
where tuberculin testing is considered inappropriate	

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>

Drug Interactions	Drug Interactions
Contraindications for Co-administration	Contraindications for Co-administration
Corticosteroid	(deleted)
Prednisolone, etc.	
(except when ointment is applied to non-injection sites)	
Precautions for Co-administration	Precautions for Co-administration
(N/A)	Corticosteroid
	Prednisolone, etc.
	(except when ointment is applied to non-injection sites)

N/A: Not Applicable, because the section is not included in the current package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>